A
What happened
A child has died following an experimental gene therapy for STXBP1 encephalopathy, developed by Capsida Biotherapeutics. The company is investigating the circumstances surrounding the incident, which raises concerns about the safety of new gene therapies.
★
Key insights
-
1
Experimental Treatment
The gene therapy was aimed at treating a rare neurological disorder.
-
2
Investigation Underway
Capsida Biotherapeutics is working to understand the cause of the child's death.
-
3
Safety Concerns
The incident raises questions about the safety of new gene therapies.
Takeaways
The death of the child highlights the risks associated with experimental medical treatments.